Yeh Ta Investment Co. Ltd.

eureKARE co-founds EonBio to revolutionize drug discovery with pioneering cell-free technology on a chip eureKARE announces EonBio as the second company to be supported by its Belgium biomedical start-up studioEonBio is developing pioneering platform technology to innovate drug discovery, design and developmentEonBio has been co-founded by eureKARE, Yeda, the commercial arm of the Weizmann Institute of Science, and built on the innovative research of Professor Roy Bar-Ziv’s lab Luxembourg, Belgium, and Paris, France – 22 February 2023: eureKARE, an innovative investment company for disruptive synthetic biology applications, announces the second company to be supported and housed in its biomedical start-up studio in Brussels, Belgium. EonBio is developing a cutting-edge platform to address high unmet medical needs by reconstructing intricate bioproduction systems akin to the ones found in living cells. By engineering living material on silicon chips, the complex synthesis of proteins, metabolites, and other useful biomaterials can be streamlined and scaled. Referred to as “cell-free technology on a chip”, this cutting-edge platform has multiple potential applications in drug discovery, design and development as well as in biomanufacturing. EonBio was co-founded by eureKARE and Yeda, the commercial arm of the Weizmann Institute of Science in Israel. The company has an exclusive license from Yeda for the "cell-free technology" platform developed by world-renowned synthetic biology leader, Prof Roy Bar-Ziv, and his team, including senior staff scientist Dr. Shirley Daube, and other colleagues. Prof Bar-Ziv was the winner of the eureKAWARDS 2021, a science-based pitch contest aimed at discovering and supporting pioneering synthetic biology projects. His lab’s project, integrating physics and biology, was praised by the jury for its scientific excellence and highly disruptive approach to many medical challenges. By being able to recreate some of the specific pieces of cellular machinery on silicon chips without the unwanted interferences usually found in real, living cells we can expect to drastically accelerate the pace of therapeutic innovation. Drug discovery, the process of exploring potential new medicines, is at the heart of R&D efforts of pharma and biotech companies around the world. Although the global drug discovery market is expected to continue growing — with projections to reach $120.8 billion by 2030 at an annual growth rate of 9.16% —, finding and developing novel and effective drugs is still costly and time consuming. But what if it didn’t have to be? Experts have realized that new tools and methodologies have the potential to revolutionize drug discovery, design and development, enabling the industry to produce more effective medicines faster and more economically. eureKARE’s Biomedical Start-up StudioeureKARE’s biomedical start-up studio is focused on creating the next generation of cell and gene therapies using disruptive synthetic biology tools and approaches. The studio in Belgium is part of eureKARE’s synthetic biology studio network, a new model of start-up creation and development which nurtures high-quality European synthetic biology. It acts as a catalyst, enabling scientists to transform their discoveries into ground-breaking businesses. eureKARE aims to nurture young innovations into successful companies, empowering scientists with the right resources, access to funding, as well as both academic and scientific know-how. Alexandre Mouradian, Chairman, Founder, and Chief Executive Officer of eureKARE, commented: “I am delighted to welcome EonBio and Prof Bar-Ziv to our biomedical start-up studio. Beyond investing in scientific projects and building new start-ups, eureKARE seeks to build synergies with leading institutions and researchers that share similar values, mission and vision to make an impact on tomorrow through synthetic biology.” Dr. Georges Rawadi, Chief of Biotech Studio Development at eureKARE, commented: “I am thrilled to be working with the highly-talented Prof Bar-Ziv and the Weizmann Institute of Science − one of the world’s leading research institutions with a long and extremely successful history of technology transfer. I look forward to equipping EonBio with the necessary resources and business expertise to boost it from proof-of-concept to industry game-changer.” Prof Bar-Ziv, Department of Chemical & Biological Physics at the Weizmann Institute of Science, commented: “After many years of dedicated research, we are honored to join forces with eureKARE in launching EonBio. Our mission is to apply insights from our lab to drive advancements in Pharma R&D. EonBio’s advanced synthetic cell-free platform has the potential to transform the way pharmaceutical companies approach drug discovery, vaccine development, and bioproduction, making it a valuable tool in the pursuit of more effective therapeutics.” - Ends - About eureKARE eureKARE is an investment company focused on financing and developing synthetic biology innovation across Europe. Driven by the belief that synthetic biology holds the key to many of the world’s most pressing health and environmental challenges, eureKARE’s experienced team is focused on harnessing Europe’s untapped leadership in the field to build the companies of the future. eureKARE is championing a new model of start-up creation and development to create a dynamic ecosystem of early and later stage ventures through its network of biotech studios. eureKARE’s studios act as a bridge between academia and industry, helping to catalyze innovations into companies with access to all the ingredients they need to grow, prosper, and bring benefits to society. About Yeda Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda currently manages approximately 500 unique patent families and has generated the highest income per researcher compared to any other academic technology transfer operation worldwide. Through the years, Yeda has contributed the commercialization of several groundbreaking therapies, such as Copaxone, Rebif, Tookad®, Erbitux®, Vectibix®, Protrazza®, Humira®, and recently the CAR-T cancer therapy Yescarta®. About the Weizmann Institute of Science The Weizmann Institute of Science in Israel is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, Weizmann Institute's scientists are advancing research on the human brain, artificial intelligence, computer science and encryption, astrophysics, and particle physics, and are tackling diseases such as cancer, while also addressing climate change through environmental, ocean, and plant sciences. Contacts eureKARE SA Michelle Wilson-André, Head of Communicationsmichelle.wilson@eurekare.eu Consilium Strategic Communications – Media RelationsAmber Fennell, Sukaina Virji, Genevieve Wilson eurekare@consilium-comms.com

PARIS--( BUSINESS WIRE )--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from February 15, 2023 to March 15, 2023 at 12:00 (noon). Interested candidates are invited to contact: SELARL FHB, Administrateurs Judiciaires Associés Me Helene BOURBOULOUX, 176, avenue Charles de Gaulle 92200 Neuilly-sur-Seine e-mails : henri.loqueville@fhbx.eu carla.messadia@fhbx.eu Access to an electronic data room will be authorized after a confidentiality undertaking and a brief presentation of the candidate. As a reminder, the search for buyers is part of the ongoing reorganization proceedings opened by decision of the Commercial Court of Nanterre on January 24, 2023. In this context, the listing of Lysogene's shares will remain suspended. About Lysogene Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable delivery of gene therapies to the CNS to treat lysosomal diseases and other disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA is ongoing. An adaptive clinical trial in GM1 gangliosidosis is also ongoing. Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism. The Company also entered into an exclusive worldwide license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a novel gene therapy candidate for Parkinson disease with GBA1 mutations. www.lysogene.com . Forward Looking Statement This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs, (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2021 universal registration document, registered with the French Markets Authorities on April 19, 2022, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

PARIS--( BUSINESS WIRE )--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it has requested, jointly with the judicial administrator, the conversion of safeguard proceedings, opened on December 13, into reorganization proceedings. The Commercial Court of Nanterre will rule on this request in the coming days. This request for conversion is motivated by the fact that safeguard proceedings did not lead to the identification of a solution to strengthen Lysogene's financial situation and to secure its cash runway. The conversion of safeguard proceedings into reorganization proceedings will allow Lysogene to further investigate solutions for the continuation of its activities and to conduct a search for buyers or investors. In this context, a bidding process for the purpose of finding buyers or investors will be published today. The deadline for the submission of offers has been set by the judicial administrator to February 15, 2023 at 12:00 am. Interested candidates are invited to contact: SELARL FHB, Administrateurs Judiciaires Associés Me Helene BOURBOULOUX, 176, avenue Charles de Gaulle 92200 Neuilly-sur-Seine e-mails : henri.loqueville@fhbx.eu carla.messadia@fhbx.eu Access to an electronic data room will be authorized after a confidentiality undertaking and a brief presentation of the candidate. In anticipation of this announcement, Lysogene has requested Euronext Paris to suspend trading of its shares as of the opening of the market today. The market will be regularly informed on the progress of the process and, more generally, on the financial situation of Lysogene. About Lysogene Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable delivery of gene therapies to the CNS to treat lysosomal diseases and other disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA is ongoing. An adaptive clinical trial in GM1 gangliosidosis is also ongoing. Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism. The Company also entered into an exclusive worldwide license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a novel gene therapy candidate for Parkinson disease with GBA1 mutations. www.lysogene.com . Forward Looking Statement This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs, (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2021 universal registration document, registered with the French Markets Authorities on April 19, 2022, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.